12:00 AM
Jun 30, 2014
 |  BC Week In Review  |  Company News  |  Other News

InVivo Therapeutics neurology news

InVivo will reduce headcount by 14 (28%) to 36 and will discontinue development of its hydrogel drug delivery program, which was in an “early stage” of preclinical development. The company said the move will save about $3 million annually and will reduce...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >